3vlg: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,615 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,615 edits
No edit summary
Line 1: Line 1:
[[Image:3vlg.jpg|left|200px]]
<!--
The line below this paragraph, containing "STRUCTURE_3vlg", creates the "Structure Box" on the page.
You may change the PDB parameter (which sets the PDB file loaded into the applet)
or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
or leave the SCENE parameter empty for the default display.
-->
{{STRUCTURE_3vlg|  PDB=3vlg  |  SCENE=  }}  
{{STRUCTURE_3vlg|  PDB=3vlg  |  SCENE=  }}  
===Crystal structure of the W150A mutant LOX-1 CTLD showing impaired OxLDL binding===
===Crystal structure of the W150A mutant LOX-1 CTLD showing impaired OxLDL binding===
{{ABSTRACT_PUBMED_22369967}}


==Disease==
[[http://www.uniprot.org/uniprot/OLR1_HUMAN OLR1_HUMAN]] Note=Independent association genetic studies have implicated OLR1 gene variants in myocardial infarction susceptibility.<ref>PMID:12384789</ref><ref>PMID:12807963</ref><ref>PMID:15060104</ref><ref>PMID:15276231</ref><ref>PMID:15860461</ref>  Note=OLR1 may be involved in Alzheimer disease (AD). Involvement in AD is however unclear: according to some authors (PubMed:12354387, PubMed:12810610 and PubMed:15976314), variations in OLR1 modify the risk of AD, while according to other (PubMed:15000751 and PubMed:15060104) they do not.<ref>PMID:12384789</ref><ref>PMID:12807963</ref><ref>PMID:15060104</ref><ref>PMID:15276231</ref><ref>PMID:15860461</ref>


<!--
==Function==
The line below this paragraph, {{ABSTRACT_PUBMED_22369967}}, adds the Publication Abstract to the page
[[http://www.uniprot.org/uniprot/OLR1_HUMAN OLR1_HUMAN]] Receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria.<ref>PMID:9052782</ref><ref>PMID:11821063</ref><ref>PMID:12354387</ref>  
(as it appears on PubMed at http://www.pubmed.gov), where 22369967 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_22369967}}


==About this Structure==
==About this Structure==
Line 22: Line 13:


==Reference==
==Reference==
<ref group="xtra">PMID:022369967</ref><references group="xtra"/>
<ref group="xtra">PMID:022369967</ref><references group="xtra"/><references/>
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Katayanagi, K.]]
[[Category: Katayanagi, K.]]
Retrieved from "https://proteopedia.org/3vlg"